Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients

Seung Hwan Lee, Cheol Young Oh, Kyung Kgi Park, Mun Su Chung, Se Jeong Yoo, Byungha Chung

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this 12-week prospective observational study, a total of 175 patients aged ≥40 years with International Prostate Symptom Scores (IPSS) ≥12 points and prostate volume ≥20ml were prospectively enrolled. The patients were divided into two groups according to BMI or WC. Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4mg once per day for 12 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Q max), post-void residual volume, quality of life (QoL) scores and adverse events (AEs) were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven patients had BMI 23kg m -2, and 43 had WC >90cm. Obese patients represented by WC >90cm or BMI ≥23kg m -2 had a significantly greater prostate volume compared with non-obese patients at baseline. Total IPSS was significantly higher in the WC >90cm group compared to the WC 90cm group. Total IPSS was positively correlated with prostate volume (P=0.031) and WC (P=0.045). All groups showed significant improvements in total IPSS and QoL at 12 weeks. However, the improvement of total IPSS was greater in the high-BMI and high-WC groups. The most frequent AE was dizziness (n=13), and it was significantly lower in the obese BPH patients. Obesity was associated with increased prostate volume and lower urinary tract symptoms. Alpha-blockers appear to be efficacious for controlling symptoms, especially in obese men.

Original languageEnglish
Pages (from-to)728-731
Number of pages4
JournalAsian Journal of Andrology
Volume13
Issue number5
DOIs
Publication statusPublished - 2011 Sep 1

Fingerprint

Prostatic Hyperplasia
Waist Circumference
Prostate
Body Mass Index
Therapeutics
Obesity
Quality of Life
Doxazosin
Lower Urinary Tract Symptoms
Residual Volume
Dizziness
Observational Studies
Prospective Studies

All Science Journal Classification (ASJC) codes

  • Urology

Cite this

Lee, Seung Hwan ; Oh, Cheol Young ; Park, Kyung Kgi ; Chung, Mun Su ; Yoo, Se Jeong ; Chung, Byungha. / Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. In: Asian Journal of Andrology. 2011 ; Vol. 13, No. 5. pp. 728-731.
@article{c356acbc24d84b068aa1ee70b9da7196,
title = "Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients",
abstract = "We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this 12-week prospective observational study, a total of 175 patients aged ≥40 years with International Prostate Symptom Scores (IPSS) ≥12 points and prostate volume ≥20ml were prospectively enrolled. The patients were divided into two groups according to BMI or WC. Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4mg once per day for 12 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Q max), post-void residual volume, quality of life (QoL) scores and adverse events (AEs) were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven patients had BMI 23kg m -2, and 43 had WC >90cm. Obese patients represented by WC >90cm or BMI ≥23kg m -2 had a significantly greater prostate volume compared with non-obese patients at baseline. Total IPSS was significantly higher in the WC >90cm group compared to the WC 90cm group. Total IPSS was positively correlated with prostate volume (P=0.031) and WC (P=0.045). All groups showed significant improvements in total IPSS and QoL at 12 weeks. However, the improvement of total IPSS was greater in the high-BMI and high-WC groups. The most frequent AE was dizziness (n=13), and it was significantly lower in the obese BPH patients. Obesity was associated with increased prostate volume and lower urinary tract symptoms. Alpha-blockers appear to be efficacious for controlling symptoms, especially in obese men.",
author = "Lee, {Seung Hwan} and Oh, {Cheol Young} and Park, {Kyung Kgi} and Chung, {Mun Su} and Yoo, {Se Jeong} and Byungha Chung",
year = "2011",
month = "9",
day = "1",
doi = "10.1038/aja.2011.5",
language = "English",
volume = "13",
pages = "728--731",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "5",

}

Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients. / Lee, Seung Hwan; Oh, Cheol Young; Park, Kyung Kgi; Chung, Mun Su; Yoo, Se Jeong; Chung, Byungha.

In: Asian Journal of Andrology, Vol. 13, No. 5, 01.09.2011, p. 728-731.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the clinical efficacy of medical treatment of symptomatic benign prostatic hyperplasia between normal and obese patients

AU - Lee, Seung Hwan

AU - Oh, Cheol Young

AU - Park, Kyung Kgi

AU - Chung, Mun Su

AU - Yoo, Se Jeong

AU - Chung, Byungha

PY - 2011/9/1

Y1 - 2011/9/1

N2 - We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this 12-week prospective observational study, a total of 175 patients aged ≥40 years with International Prostate Symptom Scores (IPSS) ≥12 points and prostate volume ≥20ml were prospectively enrolled. The patients were divided into two groups according to BMI or WC. Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4mg once per day for 12 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Q max), post-void residual volume, quality of life (QoL) scores and adverse events (AEs) were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven patients had BMI 23kg m -2, and 43 had WC >90cm. Obese patients represented by WC >90cm or BMI ≥23kg m -2 had a significantly greater prostate volume compared with non-obese patients at baseline. Total IPSS was significantly higher in the WC >90cm group compared to the WC 90cm group. Total IPSS was positively correlated with prostate volume (P=0.031) and WC (P=0.045). All groups showed significant improvements in total IPSS and QoL at 12 weeks. However, the improvement of total IPSS was greater in the high-BMI and high-WC groups. The most frequent AE was dizziness (n=13), and it was significantly lower in the obese BPH patients. Obesity was associated with increased prostate volume and lower urinary tract symptoms. Alpha-blockers appear to be efficacious for controlling symptoms, especially in obese men.

AB - We aimed to investigate the difference in efficacy of medical treatment of symptomatic benign prostatic hyperplasia (BPH) between normal and obese patients with BPH; obesity was determined by either body mass index (BMI) or waist circumference (WC). In this 12-week prospective observational study, a total of 175 patients aged ≥40 years with International Prostate Symptom Scores (IPSS) ≥12 points and prostate volume ≥20ml were prospectively enrolled. The patients were divided into two groups according to BMI or WC. Patients received the doxazosin gastrointestinal therapeutic system (GITS) at a dose of 4mg once per day for 12 weeks. The changes from baseline in the IPSS, maximal urinary flow rate (Q max), post-void residual volume, quality of life (QoL) scores and adverse events (AEs) were analysed. Of the 175 enrolled patients, 132 completed the study. Sixty-seven patients had BMI 23kg m -2, and 43 had WC >90cm. Obese patients represented by WC >90cm or BMI ≥23kg m -2 had a significantly greater prostate volume compared with non-obese patients at baseline. Total IPSS was significantly higher in the WC >90cm group compared to the WC 90cm group. Total IPSS was positively correlated with prostate volume (P=0.031) and WC (P=0.045). All groups showed significant improvements in total IPSS and QoL at 12 weeks. However, the improvement of total IPSS was greater in the high-BMI and high-WC groups. The most frequent AE was dizziness (n=13), and it was significantly lower in the obese BPH patients. Obesity was associated with increased prostate volume and lower urinary tract symptoms. Alpha-blockers appear to be efficacious for controlling symptoms, especially in obese men.

UR - http://www.scopus.com/inward/record.url?scp=80052483248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052483248&partnerID=8YFLogxK

U2 - 10.1038/aja.2011.5

DO - 10.1038/aja.2011.5

M3 - Article

VL - 13

SP - 728

EP - 731

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 5

ER -